

Your benefit

The partner country of the international ZIM cooperation network is Canada with the aim of promoting and supporting German-Canadian research and development collaborations. A diverse network of R&D partners is needed to support the research and technological developments to explore the full potential and usage of cannabis as a medical plant, while meeting the given legal requirements in Germany.

The network will encourage partnerships between German and Canadian companies as well as between research and technology organizations (RTOs) and develop the strategic links between the partners in both countries, to facilitate market access and the exchange of technologies.

Are you interested in our network?

Contact us.



UNIVERSITY OF
HOHENHEIM

Canada

Network Management

University of Hohenheim

Prof. Dr. Simone Graeff-Hönninger

Phone +49 (0)711-459 22376

Email: graeff@uni-hohenheim.de

Samantha Jo Grimes

Phone +49 (0)711-459 24184

Email: s.grimes@uni-hohenheim.de

Katrin Scherer

Phone +49 (0)711-459 24185

Email: katrin.scherer@uni-hohenheim.de

National Research Council - Industrial Research Assistance Program (NRC-IRAP)

Andrew Bauder

Phone +1 (0)905-849-7441

Email: andrew.bauder@nrc-cnrc.gc.ca

We would like to thank the following institutions
for their generous support:



Supported by:



on the basis of a decision
by the German Bundestag



International ZIM Cooperation Network

MEDICAL
PHYTOCANNABINOID-RICH
CANNABIS

The goals of the network are three-fold:

- Link scientists and industry partners in Germany and Canada with complementary expertise,
- Set up collaborative research projects in the area of cannabis (THC-rich) and PCR-rich (rich in CBD, CBG, CBC but low in THC) to close existing technological and service based gaps,
- Exchange knowledge in both directions and open up market opportunities for the industrial partners in both countries.

The partners will use cutting-edge approaches to achieve targeted improvements in cannabis breeding, productivity, applicability and raw material quality for end-user requirements

The network will bring together leading research groups in both countries with a vibrant group of industrial participants working from the level of agronomy through to end product development.



Vision

In order to capture the potential market potential of companies in this tightly regulated market, technological developments along the entire value chain are required, which entail high economic and technical risks.

The vision of the network is to advance the opening cannabis market in Germany by developing targeted, urgently needed technological innovations in the value chain of cannabis and thus to lay the foundation for future economic growth.

In order to meet the given requirements of a standardized cannabis production, German industry and research organizations have to link up with experienced partners in this sector to close existing knowledge gaps.

To comply with the demands of the pharmaceutical industry and the evolving cannabis market for both THC-rich and PCR-rich/low THC-strains, the network will contribute to a better understanding of the cannabis plant, its relevant pharmacological compounds focusing on CBD, CBC, CBG etc., and its further potential health benefits resulting out of a yet unexploited set of compounds like terpenoids, flavonoids etc..

Priorities and objectives

The overall objective within the network is the development of new cannabis products and new required technologies along the cannabis value chain, respectively.



Breeding and cultivation

Breeding and Selection of PCR Genetics with High CBD, CBG, CBC Levels.



Machinery / Harvesting Technology

Machine-integrated, robust GACP / GMP-compliant field and process measurements.



Plant engineering / drying

Development of suitable low temperature drying methods for cannabis.



Analytics / measuring technology

Active substance assays to assess the bioavailability of cannabinoids.



Data technology

Software development for GMP.



End application / Certification

Final product development including dosage form and galenics.